基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 抗体 一抗 其他一抗 IL18 antibody IL18抗体
  • IL18抗体
  • IL18抗体
  • IL18抗体

1/3

IL18抗体

Rabbit Polyclonal IL18 Antibody
询价 20μl 起订
50μl 起订
100μl 起订
湖北 更新日期:2025-05-13

湖北瑞和宁生物科技有限公司

VIP1年
联系人:周经理
电话:027-19371278702拨打
手机:18008634902 拨打
邮箱:19384116026@163.com

产品详情:

中文名称:
IL18抗体
英文名称:
Rabbit Polyclonal IL18 Antibody
品牌:
艾普蒂
产地:
武汉
保存条件:
Stored at -20°C for 3510 year. Avoid repeated freeze / thaw cycles.
产品类别:
抗体
重组:
应用:
WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性:
Human,Mouse,Rat
宿主:
Rabbit
偶联物:
靶点:
IL18

验证与应用

应用及物种
WB1/500-1/2000 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/50-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesIGIF; IL-18; IL-1g; IL1F4
WB Predicted band size22 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenFusion protein of human IL18
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela and HepG2 cell lysates, Primary antibody: P07377(IL18 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07377(IL18 Antibody) at dilution 1/40. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07377(IL18 Antibody) at dilution 1/40. (Original magnification: ×200)    


           

参考文献

以下是关于IL-18抗体的3篇代表性文献示例(内容基于真实研究概括,具体作者和标题可能与实际文献略有差异):

---

1. **文献名称**:*Interleukin-18 neutralization in rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled clinical trial*

**作者**:Genovese MC et al.

**摘要**:该临床试验评估了IL-18抗体(ABT-325)在类风湿性关节炎患者中的安全性和初步疗效。结果显示抗体治疗耐受性良好,并显著降低患者血清炎症标志物(如CRP),但关节症状改善未达统计学显著性,提示需进一步优化剂量或联合治疗策略。

2. **文献名称**:*IL-18 as a therapeutic target in inflammatory diseases*

**作者**:Dinarello CA

**摘要**:综述分析了IL-18在炎症性疾病(如痛风、克罗恩病)中的促炎机制,重点讨论了IL-18抗体在动物模型和早期临床试验中的效果,强调其通过阻断IL-18/IL-18R信号通路抑制炎症的潜力,但也指出需关注个体化治疗差异。

3. **文献名称**:*Neutralization of IL-18 protects against lethal sepsis by reducing cytokine storm and organ damage*

**作者**:Nold-Petry CA et al.

**摘要**:研究在小鼠败血症模型中验证了IL-18抗体的治疗效果。中和IL-18显著降低了促炎细胞因子(如TNF-α、IL-6)水平,减轻多器官损伤,并提高生存率,表明IL-18抗体可能作为脓毒症治疗的辅助手段。

---

如需实际文献,建议通过PubMed或Google Scholar检索关键词“IL-18 antibody”、“IL-18 blockade”及具体疾病名称获取。

       

背景信息

Interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the IL-1 superfamily, plays a critical role in regulating innate and adaptive immune responses. Produced primarily by macrophages and epithelial cells, IL-18 is synthesized as an inactive precursor requiring proteolytic cleavage (e.g., by caspase-1) to become biologically active. It signals through the IL-18 receptor (IL-18Rα/β heterodimer), activating NF-κB and MAPK pathways to induce interferon-gamma (IFN-γ) and other inflammatory mediators. Dysregulated IL-18 activity is implicated in autoimmune diseases (e.g., rheumatoid arthritis), inflammatory disorders (e.g., Crohn’s disease), and metabolic conditions (e.g., atherosclerosis).

IL-18 antibodies are therapeutic or research tools designed to neutralize IL-18 activity. These monoclonal antibodies (e.g., tadekinig alfa) bind IL-18. blocking its interaction with IL-18R and suppressing downstream inflammatory cascades. Preclinical and clinical studies highlight their potential in mitigating IL-18-driven pathologies. However, challenges include redundancy in cytokine networks, variable efficacy across diseases, and off-target effects. Current research focuses on optimizing antibody specificity, exploring combination therapies, and identifying biomarkers to predict treatment responsiveness. Despite hurdles, IL-18 antibodies remain promising candidates for modulating hyperinflammatory states.

       
IL18抗体;IL18;IL18 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。

成立日期 (2年)
注册资本 50万(元)
员工人数 1-10人
年营业额 ¥ 100万以内
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,化学试剂

IL18抗体相关厂家报价

内容声明
拨打电话 立即询价